WO2009077352A1 - Prevention of opportunistic infections in immune-compromised subjects - Google Patents
Prevention of opportunistic infections in immune-compromised subjects Download PDFInfo
- Publication number
- WO2009077352A1 WO2009077352A1 PCT/EP2008/066850 EP2008066850W WO2009077352A1 WO 2009077352 A1 WO2009077352 A1 WO 2009077352A1 EP 2008066850 W EP2008066850 W EP 2008066850W WO 2009077352 A1 WO2009077352 A1 WO 2009077352A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- probiotic
- immune
- bifidobacterium
- composition according
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Definitions
- This invention relates to the prevention of opportunistic infections in immune- compromised subjects, particularly premature and neo-natal infants.
- the immune system of a healthy new-born infant is not as effective as that of an older healthy child or a healthy adult. To a great extent, this is because the newborn infant has yet Io encounter potential antigens and the B cells and T cells have yet to mature such that they can mount appropriate immune responses. The newborn infant is not completely unprotected against pathogens because maternal
- EP 0 199 535 discloses specific strains of Lactobacilli and Bifidobacteria and their beneficial effects.
- EP 0 768 375, WO 97/00078, EP 0 577 903 and WO 00/53200 disclose specific strains of Lactobacilli and Bifidobacteria and their beneficial effects.
- the present inventors have surprisingly found that the co-administration of certain probiotic Bifidobacteria and a fucosylated oligosaccharide is particularly effective in the prevention of opportunistic infections in immune-compromised indivduals such as preterm and neonatal infants.
- the present invention provides a composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals comprising a probiotic Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium b ⁇ eve or Bifidobacterium longum and a fiicosylated oligosaccharide selected from the group comprising 2 '-fucosyllactose, 3 ' fucosyllactose, ciifucosyllactose, lacto-N-fucopentaose, lacto-N-fucohexaose, fucosyllacto-N-tiexaose and fucosyllacto-N-neohexaose.
- the present invention provides the use of a probiotic Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve or Bifidobacterium longum and a fucosylated oligosaccharide selected from the group comprising 2'-li ⁇ :osyHactose, 3 fucosyllactose, difucosyllactose, lacto-N- fucopentaose, lactc -N-fucohexaose, fucosyllacto-N-hexaose and fucosyllacto-N- neohexaose in the n ⁇ anuf acture of a composition for the prevention of opportunistic infections in immune-compromised individuals.
- a fucosylated oligosaccharide selected from the group comprising 2'-li ⁇ :osyHactose, 3 fucosyllactose, dif
- the invention further extends to a method for the prevention of opportunistic infections in immune-compromised individuals which comprises administering to an individual in need thereof a therapeutic amount of a probiotic Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve or Bifidobacterium longum and a fucosylated oligosaccharide selected from the group comprising T- fucosyllactose, 3 ' fucosyl lactose, difucosyllactose, lacto-N-fucopentaose, lacto-N- fucohexaose, fucosvllacto-N-hexaose and fucosyllacto-N-neohexaose.
- a fucosylated oligosaccharide selected from the group comprising T- fucosyllactose, 3 ' fucosyl lactose, difucosyllactose
- the inventors believe that the efficacy of the combination of prob;otic and fucosylated oligosaccharide described above in the prevention of opportunistic infections in immune-compromised subjects may be a result of synergks between the specific probiotic and oligosaccharide. It is known that human milk contains a complex array of oligosaccharides including fucosylated and sial plated species. The functions of all these oligosaccharides have not yet been fully elucidated but it has been hypothesised that one of their functions is to act as a metabolic fuel for the intestinal microbiota.
- An optimal intestinal microbiota for human infants is dominated by various species of Bifidobacteria and it had been thought ihat one of the functions of the oligosaccharides in human milk was to serve as a fermentation substrate and/or metabolic stimulus specifically for Bifidobacteria, thereby favouring growth and/or metabolic activity of these species at the expense of less desirable anaerobes such as Clostridia and Bacteroides.
- follow-on formula ' means a foodstuff intended for particular nutritional use by infants aged over four months and constituting the principal liquid element in the progressively diversified diet of this category of person;
- “growing up milk ' means a milk based beverage adapted for the specific nutritional needs of young children
- immune-compromised individual means an individual with an immune system which is immature or otherwise not fully effective such that the individual is vulnerable to infection b> opportunistic pathogens;
- ⁇ "infant” means a child under the age of 12 months
- infant formula ' ' means a foodstuff intended for particular nutritional use by infants during the first four to six months of life and satisfying by itself the nutritional requirements of this category of person;
- neonatal infanf me ans a full-term infant under the age of one month
- opportunistic pathogen means a pathogen which has no effect on a healthy individual but which can cause a variety of infections in an immune-compromised individual
- prevention of opportunistic infections' includes reduction of risk and/or severity of such infections
- probiotic means microbial cell preparations or components of microbial cells with a beneficial effect on the health or well-being of the host.
- the immune-compromised individual may be a premature or neonatal infant.
- the irnmune-compromised individual may be an older child or adult with an immune svstem which is not fully effective as a result of an existing condition or illness -uch as infection with human immunodeficiency virus (HIV) or as a result of therapy for an existing condition such as immuno-suppressive drugs for the treatment o ' aut>immune conditions eg Crohn's disease or rheumatoid arthritis or chemo -therapy for the treatment of cancer.
- HIV human immunodeficiency virus
- Suitable probiolic B ifidobacteria include Bifidobacterium lactis CNCM 1-3446 sold inter alia by the Christian Hansen company of Denmark under the trade mark Bb 12. Bifidobacterium longum ATCC BAA-999 sold by Morinaga Milk Industry Co. Ltd.
- a suitable daily dose of the probiotic bacteria is from 10e3 to 1Oe 12 colony forming units (cfu), more preferably from 10e7 to lOel 1 cfu.
- fucosylated oligosaccharide may be selected from the group comprising 2 -fucosyllactose, 3 'fucosyllactose, difucosyllactose, lacto-N- lucopentaose, lacto-N-f ⁇ cohexaose, fucosyllacto-N-hexaose and fucosyllacto-N- neohexaose.
- a particularly preferred fucosylated oligosaccharide is T- fucosyllactose (2FL).
- DP degree of polymerisation
- fucosylated oligosaccharides may be produced by chemical synthesis starting with lacto-e and free fucose. Fucosylated oligosaccharides are also available for example from Kyowa Hakko Kogyo of Japan.
- the fucosylated oligosaccharide and probiotic Bifidobacteria may be administered in the same composition ar may be administered sequentially.
- the opportunistic infections which may be prevented according to the invention include infections of the respiratory, urinary or gastrointestinal tracts by Acinetobacter bavmannii, Staphylococcus aureus, Clostridium difficile, Pseudomonas aeruginosa or Candida albicans for example.
- the invention is particularly suitable; for the prevention of opportunistic infections including necrotising enterocolitis m premature or neonatal infants.
- the invention is also suitable for the 1 prevention of nosocomial infections in immune-compromised subjects.
- the composition is preferably an infant formula.
- an infant formula according to the invention contains from 0.1 to 3g fucosylated oligosaecharide/lOOg infant formula on a dry weight basis and from 10e3 to 1Oe 12 cfu/g infant formula, more preferably 10e6 to 10e9 cfu/g of the probiotic Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve or Bifidobacterium Ionium.
- An infant formula according to the invention preferably further contains at least one prebiotic in an amount of 0.3 to 10%.
- a prebiotic is a non-digestible food ingredient that beneficially affects the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon, and thus improves host health. Such ingredients are non-digestible in the sense that they are not broken down and absorbed in the stomach or small intestine and thus pass intact to the colon where they are selectively fermented by the beneficial bacteria.
- prebiotics include certain oligosaccharides, such as fructooligosaccharides (FOS) and galactooligosaccharides (GOS).
- a combination of prebiotics may be used such as 90% GOS with 10% short chain fructo-oligosac char ides such as the product sold under the trade mark Raftilose® or 10% inulin such as the product sold under the trade mark Raftiline®.
- a particularly preferred combination of prebiotics is 70% short chain fructo- oligosaccharides and 30% inulin.
- the general composition of an infant formula according to the invention will now be described by way of example.
- the formula contains a protein source.
- protein sources based on whey, casein and mixtures thereof may be used as well as protein sources based on soy.
- the protein source may be based on acid whey or sweet whey or mixtures thereof and may include alpha-lactalbumin and beta- lactoglobulin in whatever proportions are desired.
- the proteins may be intact or hydrolysed or a mixture of intact and hydrolysed proteins. It may be desirable to supply partially hydrolysed proteins (degree of hydrolysis between 2 and 20%), for example for infants believed to be at risk of developing cows' mill; allergy. If hydrolysed proteins are required, the hydrolysis process may be carried out as desired and as is known in the art. For example, a whey proiein hydrolysate may be prepared by enzymatically hydrolysing the whey fraction in one or more steps. If the whey fraction used as the starting material is substantially lactose free, it is found that the protein suffers much less lysine blockage during the hydrolysis process. This enables the extent of lysine blockage to be reduced from about 15% by weight of total lysine to less than about 10% by weight of lysine; for example about 7% by weight of lysine which greatly improves the nutritional quality of the protein source.
- An infant formula according to the present invention contains a carbohydrate source.
- Any carbohydrate source conventionally found in infant formulae such as lactose, saccharose, maltodextri n, starch and mixtures thereof may be used although the preferred source of carbohydrates is lactose.
- the carbohydrate sources contribute between 35 and 65% of the total energy of the formula.
- An infant form ⁇ la according to the present invention contains a source of lipids.
- the lipid source may be any lipid or fat which is suitable for use in infant formulas.
- Preferred fat sources include palm olein, high oleic sunflower oil and high oleic safflowe r oil.
- the essential fatty acids linoleic and ⁇ -linolenic acid may also be added as may small amounts of oils containing high quantities of preformed arachidonic acid and docosahexaenoic acid such as fish oils or microbial oils. Ir total, the fat content is preferably such as to contribute between 30 to .'55% of the total energy of the formula.
- the fat source preferably has a ratio of n-6 to n-3 fatty acids of about 5: 1 to about 15:1 ; for example about 8: 1 to about 10 1.
- the infant formula will also contain all vitamins and minerals understood to be essential in the: daily diet and in nutritionally significant amounts. Minimum requirements have been sstablished for certain vitamins and minerals.
- minerals, vitamins and other nutrients optionally present in the infant formula include vitamin A, /itamin Bl, vitamin B2, vitamin B6, vitamin B 12, vitamin E, vitamin K, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calc ium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloric e, potassium, sodium, selenium, chromium, molybdenum, taurine, and L- carnitine. Minerals are usually added in salt form. The presence and amounts o f specific minerals and other vitamins will vary depending on the intended infant population.
- the infant formula may contain emulsifiers and stabilisers such as soy lecithin, citric acid esters of mono- and di-glycerides, and the like.
- the infant formula may optionally contain other substances which may have a beneficial effeci such as lactoferrin, nucleotides, nucleosides, and the like.
- the formuL will contain 2FL in a total amount between 0.1 to 3 g of 2FL/100g forrrula and Bifidobacterium lactis CNCM 1-3446 in an amount of 2.10e7 cfu/g of formula.
- the formula may be prepared in any suitable manner. For example, it may be prepared by blending together the protein, the carbohydrate source, and the fat source in appro p ⁇ a1 ; proportions. If used, the emulsifiers may be included at this point. The vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be d ssolved into the fat source prior to blending. Water, preferably water which has been subjected to reverse osmosis, may then be mixed in to form a iquid mixture. The temperature of the water is conveniently about 50 0 C to about 80 0 C to aid dispersal of the ingredients. Commercially available liquefiers may be used to form the liquid mixture. The 2FL may be added at this stage. The liquid mixture is then homogenised; for example in two stages.
- the liquid mixture may then be thermally treated to reduce bacterial loads, by rapidly heating the liquid mixture to a temperature in the range of about 80 0 C to about 150 0 C for about 5 seconds to about 5 minutes, for example.
- This may be carried out by stea n injection, autoclave or by heat exchanger; for example a plate heat exchanger.
- the liquid mixture may be cooled to about 60 0 C to about 85°C; for example by flash c ooling.
- the liquid mixture may then be again homogenised; for example in Iwo stages at about 10 MPa to about 30 MPa in the first stage and about 2 MPa to about 10 MPa in the second stage.
- the homogenised mixture may then be lurther cooled to add any heat sensitive components; such as vitamins and minerals.
- the pH and solids content of the homogenised mixture are conveniently adjusted at this point.
- the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
- the powder should have a moisture content of less ihan about 5% by weight.
- the 2FL may be added at this stage by dry-mixing along with the probiotic.
- the composition may be a supplement including the fucosylated oligosaccharide and probiotic in an amount sufficient to achieve the desired effect in an individual.
- This form of administration is more suited to older children and adults.
- the daily dose of the fucosylated oligosaccharide is from 0.1 to 3g and the daily dose of the probiotic is from 10e5 to 1 Oe 12 cfu.
- the a mounts of fucosylated oligosaccharide and probiotic to be included in the supplement will be selected accordingly depending upon how the supplement is to be administered.
- each supplement may contain 0.05 to 1.5g fucosylated oligosaccharide 1 and 10e3to 10e6 cfu of probiotic.
- the supplement may be in the form of tablets, capsules, pastilles or a liquid for example.
- the supplement may further contain protective hydrocolloids (such as gums, proteins, modified starches), binders, ] ilm forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emulsifiers, surface active agents, solubilizing agents (oils, fats, waxes, lecithins etc.), adsorbents, carriers, fillers, co-compounds, dispersing agents, wetting agents, processing aids (solvents), flowing agents, taste masking agenis, weighting agents, jellifying agents and gel forming agents.
- protective hydrocolloids such as gums, proteins, modified starches
- binders such as gums, proteins, modified starches
- ilm forming agents such as gums, proteins, modified starches
- encapsulating agents/materials, wall/shell materials such as binders, ] ilm forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emuls
- the supplement may also contain conventional pharmaceutical additives and adjuvants, excipients and diluents, including, but not limited to, water, gelatine of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavouring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, colorants, wetting agents, fillers, and the like.
- conventional pharmaceutical additives and adjuvants, excipients and diluents including, but not limited to, water, gelatine of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavouring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, colorants, wetting agents, fillers, and the like.
- the supple: ment may contain an organic or inorganic carrier material suitable for oral or enteral administration as well as vitamins, minerals trace elements and ether micronutrients in accordance with the recommendations of Government bodies such as the USEDA.
- composition of an infant formula according to the present invention is given below. This composition is given by way of illustration only.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08862982.9A EP2234627B1 (en) | 2007-12-17 | 2008-12-05 | Prevention of opportunistic infections in immune-compromised subjects |
MYPI2010002780A MY185938A (en) | 2007-12-17 | 2008-12-05 | Prevention of opportunistic infections in immune-compromised subjects |
US12/808,053 US9217133B2 (en) | 2007-12-17 | 2008-12-05 | Prevention of opportunistic infections in immune-compromised subjects |
RU2010129685/15A RU2486910C2 (en) | 2007-12-17 | 2008-12-05 | Prevention of opportunistic infections in immune compromised individuals |
CN2008801249067A CN101909644A (en) | 2007-12-17 | 2008-12-05 | Prevention of opportunistic infections in immune-compromised subjects |
CA2709396A CA2709396A1 (en) | 2007-12-17 | 2008-12-05 | Prevention of opportunistic infections in immune-compromised subjects |
ES08862982.9T ES2576642T3 (en) | 2007-12-17 | 2008-12-05 | Prevention of opportunistic infections in immunologically compromised subjects |
BRPI0820837-9A BRPI0820837A2 (en) | 2007-12-17 | 2008-12-05 | Preparation of opportunistic infections in immunocompromised patients |
MX2010006690A MX2010006690A (en) | 2007-12-17 | 2008-12-05 | Prevention of opportunistic infections in immune-compromised subjects. |
AU2008337646A AU2008337646B2 (en) | 2007-12-17 | 2008-12-05 | Prevention of opportunistic infections in immune-compromised subjects |
UAA201008634A UA102830C2 (en) | 2007-12-17 | 2008-12-08 | Prevention of opportunistic infections in immune-compromised subjects |
ZA2010/05088A ZA201005088B (en) | 2007-12-17 | 2010-07-16 | Prevention of opportunistic infections in immune compromised subjects |
US13/588,745 US20120308527A1 (en) | 2007-12-17 | 2012-08-17 | Prevention of opportunistic infections in immune-comprised subjects |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07123390.2 | 2007-12-17 | ||
EP07123390A EP2072052A1 (en) | 2007-12-17 | 2007-12-17 | Prevention of opportunistic infections in immune-compromised subjects |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/588,745 Division US20120308527A1 (en) | 2007-12-17 | 2012-08-17 | Prevention of opportunistic infections in immune-comprised subjects |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009077352A1 true WO2009077352A1 (en) | 2009-06-25 |
Family
ID=39111664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/066850 WO2009077352A1 (en) | 2007-12-17 | 2008-12-05 | Prevention of opportunistic infections in immune-compromised subjects |
Country Status (18)
Country | Link |
---|---|
US (2) | US9217133B2 (en) |
EP (2) | EP2072052A1 (en) |
CN (1) | CN101909644A (en) |
AU (1) | AU2008337646B2 (en) |
BR (1) | BRPI0820837A2 (en) |
CA (1) | CA2709396A1 (en) |
ES (1) | ES2576642T3 (en) |
IN (1) | IN2010DE04311A (en) |
MX (1) | MX2010006690A (en) |
MY (1) | MY185938A (en) |
PH (1) | PH12010501367B1 (en) |
PL (1) | PL2234627T3 (en) |
PT (1) | PT2234627T (en) |
RU (1) | RU2486910C2 (en) |
SG (1) | SG186657A1 (en) |
UA (1) | UA102830C2 (en) |
WO (1) | WO2009077352A1 (en) |
ZA (1) | ZA201005088B (en) |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120171166A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota |
US20120171165A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
US20120202753A1 (en) * | 2009-07-06 | 2012-08-09 | Children's Hospital Medical Center D/B/A Cincinnati Children's Hospital Medical Center | Inhibiting inflammation with milk oligosaccharides |
CN102946742A (en) * | 2010-04-27 | 2013-02-27 | N·V·努特里奇亚 | Use of human milk oligosaccharides in infant nutrition |
US20130243797A1 (en) * | 2010-11-23 | 2013-09-19 | Norbert Sprenger | Composition comprising hydrolysed proteins and oligisaccharides for treating skin diseases |
US20140294789A1 (en) * | 2011-07-22 | 2014-10-02 | Abbott Laboratories | Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
US20140335065A1 (en) * | 2011-08-29 | 2014-11-13 | Abbott Laboratories | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
US9132143B2 (en) | 2007-09-07 | 2015-09-15 | The General Hospital Corporation | Use of secretor, lewis and sialyl antigen levels in clinical samples as predictors of risk for disease |
US9283240B2 (en) | 2010-12-31 | 2016-03-15 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
WO2016139333A1 (en) | 2015-03-05 | 2016-09-09 | Nestec S.A. | Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children |
WO2016139328A1 (en) | 2015-03-05 | 2016-09-09 | Nestec S.A. | Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children |
EP3111942A1 (en) | 2013-11-15 | 2017-01-04 | Nestec S.A. | Compositions for use in the prevention or treatment of urt infections in infants or young children at risk |
US9539269B2 (en) | 2010-12-31 | 2017-01-10 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
US9763465B2 (en) | 2010-11-23 | 2017-09-19 | Nestec S.A. | Oligosaccharide composition for treating acute respiratory tract infections |
US9763970B2 (en) | 2010-12-31 | 2017-09-19 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
US9795623B2 (en) | 2010-12-31 | 2017-10-24 | Abbott Laboratories | Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin C and anti-inflammatory agents |
US9808474B2 (en) | 2010-12-31 | 2017-11-07 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
WO2017215721A1 (en) * | 2016-06-15 | 2017-12-21 | Glycom A/S | Synthetic compositions comprising human milk oligosaccharides for use γν the prevention and treatment of disorders |
EP3265099A4 (en) * | 2015-03-05 | 2018-11-07 | Glycom A/S | Composition and method for treating acute respiratory tract infections |
EP2658546B1 (en) | 2010-12-31 | 2018-12-05 | Abbott Laboratories | Methods of using human milk oligosaccharides for improving airway respiratory health |
US10149870B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
US10420784B2 (en) | 2009-07-15 | 2019-09-24 | N.V. Nutricia | Mixture of non-digestible oligosaccharides for stimulating the immune system |
US10588965B2 (en) | 2009-07-15 | 2020-03-17 | N.V. Nutricia | Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit |
US10626460B2 (en) | 2013-02-21 | 2020-04-21 | Children's Hospital Medical Center | Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease |
US10668116B2 (en) | 2014-10-31 | 2020-06-02 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US10835544B2 (en) | 2014-12-08 | 2020-11-17 | Glycom A/S | Synthetic composition for regulating satiety |
US10857167B2 (en) | 2015-04-28 | 2020-12-08 | Children's Hospital Medical Center | Use of oligosaccharide compositions to enhance weight gain |
US10881674B2 (en) | 2014-12-08 | 2021-01-05 | Glycom A/S | Synthetic composition for treating metabolic disorders |
US10940158B2 (en) | 2013-11-15 | 2021-03-09 | Societe Des Produits Nestle S.A. | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by C-section |
US10987368B2 (en) | 2014-12-08 | 2021-04-27 | Glycom A/S | Synthetic composition for preventing or treating CVD |
US11109603B2 (en) | 2011-06-20 | 2021-09-07 | H.J. Heinz Company Brands Llc | Probiotic compositions and methods |
US11135232B2 (en) | 2013-11-15 | 2021-10-05 | Societe Des Produits Nestle S.A. | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children |
RU2773674C2 (en) * | 2009-07-15 | 2022-06-07 | Н.В. Нютрисиа | Mixture of indigestible oligosaccharides to stimulate immune system |
US11559539B2 (en) | 2017-08-11 | 2023-01-24 | N.V. Nutricia | Human milk oligosaccharide for improving immune fitness |
EP3981256A4 (en) * | 2019-06-05 | 2023-01-25 | Morinaga Milk Industry Co., Ltd. | Composition |
US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
WO2024013393A1 (en) | 2022-07-15 | 2024-01-18 | Dsm Ip Assets B.V. | Combination of bifidobacterium and fucosylated hmo for use in increasing nmn or nad+ |
WO2024068747A1 (en) * | 2022-09-27 | 2024-04-04 | Société des Produits Nestlé S.A. | Uses of bifidobacterium longum transitional microorganism |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2072052A1 (en) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
US9457077B2 (en) | 2009-11-18 | 2016-10-04 | Katherine Rose Kovarik | Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases |
US9585920B2 (en) | 2011-02-04 | 2017-03-07 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
US9408880B2 (en) | 2013-12-20 | 2016-08-09 | Katherine Rose Kovarik | Method and system for prevention and treatment of allergic and inflammatory diseases |
WO2011136637A1 (en) * | 2010-04-27 | 2011-11-03 | N.V. Nutricia | Use of human milk oligosaccharides in infant nutrition |
WO2011150939A1 (en) | 2010-06-01 | 2011-12-08 | Glycom A/S | Polymorphs of 2'-o-fucosyllactose and producing thereof |
EP2455387A1 (en) * | 2010-11-23 | 2012-05-23 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
US10111913B2 (en) | 2011-02-04 | 2018-10-30 | Joseph E. Kovarik | Method of reducing the likelihood of skin cancer in an individual human being |
US11191665B2 (en) | 2011-02-04 | 2021-12-07 | Joseph E. Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US10314865B2 (en) | 2011-02-04 | 2019-06-11 | Katherine Rose Kovarik | Method and system for treating cancer and other age-related diseases by extending the healthspan of a human |
US10583033B2 (en) | 2011-02-04 | 2020-03-10 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
US11357722B2 (en) | 2011-02-04 | 2022-06-14 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
US10010568B2 (en) | 2011-02-04 | 2018-07-03 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a spirochetes infection in a human being |
US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US10835560B2 (en) | 2013-12-20 | 2020-11-17 | Joseph E. Kovarik | Reducing the likelihood of skin cancer in an individual human being |
US9730967B2 (en) | 2011-02-04 | 2017-08-15 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
US10085938B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for preventing sore throat in humans |
US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
WO2012107865A2 (en) | 2011-02-10 | 2012-08-16 | Wyeth Llc | Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk |
WO2012158517A1 (en) * | 2011-05-13 | 2012-11-22 | Glycosyn LLC | The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics |
AU2012325072B2 (en) * | 2011-10-18 | 2015-12-03 | Société des Produits Nestlé S.A. | Composition for use in increasing insulin sensitivity and/or reducing insulin resistance |
BR112014008425A2 (en) * | 2011-10-18 | 2017-04-11 | Nestec Sa | composition for use in promoting intestinal angiogenesis and nutrient absorption and tolerance to enteral feeding and / or preventing and / or treating intestinal inflammation and / or recovery after injury and intestinal surgery. |
SG11201406022YA (en) * | 2012-03-27 | 2014-10-30 | Abbott Lab | Methods for modulating cell-mediated immunity using human milk oligosaccharides |
ES2572831T3 (en) * | 2012-09-14 | 2016-06-02 | Abbott Laboratories | Nutritional compositions for use in methods to modulate corticosterone levels in individuals with psychological stress |
US10165788B2 (en) * | 2013-06-17 | 2019-01-01 | The Regents Of The University Of California | Methods and compositions for improved digestion of milk oligosaccharides |
EP2815757A1 (en) * | 2013-06-17 | 2014-12-24 | Hestia Investments | Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa |
US10568896B2 (en) | 2013-11-19 | 2020-02-25 | Abbott Laboratories | Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides |
US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
CN113331426A (en) | 2014-04-08 | 2021-09-03 | 雅培公司 | Methods of using human milk oligosaccharides to enhance mucosal innate immune responses and/or detection to pathogens |
SG11201703298SA (en) * | 2014-10-24 | 2017-05-30 | Evolve Biosystems Inc | Activated bifidobacteria and methods of use thereof |
CN106998775A (en) * | 2014-11-26 | 2017-08-01 | 雅培制药有限公司 | Infant formula with RRR alpha tocopherols, 2 ' fucosyllactoses and probiotics |
AU2016227597B2 (en) * | 2015-03-05 | 2020-01-16 | Société des Produits Nestlé S.A. | Compositions for use in improving stool consistency or frequency in infants or young children |
CN109414464A (en) * | 2016-03-11 | 2019-03-01 | 进化生物系统股份有限公司 | For improving the of short duration symbiotic microorganism of intestinal health |
EP3583858A1 (en) * | 2018-06-20 | 2019-12-25 | DuPont Nutrition Biosciences ApS | Compositions for treating or preventing gut barrier dysfunction |
BR112020022892A2 (en) * | 2018-05-31 | 2021-02-23 | Glycom A/S | mixture of hmos for treatment of autoimmune diseases |
MX2022006088A (en) * | 2019-11-20 | 2022-06-14 | Abbott Lab | Nutritional compositions for treating a clostridium difficile infection. |
CN112870232A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Application of bifidobacterium lactis BL-99 in improving intestinal bacterial infection resistance and intestinal immunity |
EP4129302A4 (en) * | 2020-04-03 | 2024-04-17 | Inner Mongolia Yili Industrial Group Co., Ltd. | Breast milk oligosaccharides for improving resistance of organism against staphylococcus aureus infection |
WO2022100758A1 (en) * | 2020-11-16 | 2022-05-19 | 内蒙古伊利实业集团股份有限公司 | Composition containing bifidobacterium lactis and human milk oligosaccharides and application thereof |
CN116195629A (en) * | 2021-11-30 | 2023-06-02 | 内蒙古伊利实业集团股份有限公司 | New application of bifidobacterium infantis YLGB-1496 in resisting aging and improving innate immunity |
CN116195740A (en) * | 2021-11-30 | 2023-06-02 | 内蒙古伊利实业集团股份有限公司 | Prebiotics and probiotic compositions for improving the resistance of organisms to staphylococcus aureus infections |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0768375A1 (en) * | 1992-07-06 | 1997-04-16 | Societe Des Produits Nestle S.A. | Lactic bacteria |
WO1999056754A1 (en) * | 1998-04-30 | 1999-11-11 | Abbott Laboratories | COMPOSITIONS CONTAINING AN α1,2-FUCOSE LINKAGE AND USES THEREOF |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4839281A (en) | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
DE69223615T2 (en) | 1992-07-06 | 1998-04-09 | Nestle Sa | Antigastritis agents containing Lactobacillus Acidophilus |
FI104465B (en) | 1995-06-14 | 2000-02-15 | Valio Oy | Protein hydrolyzates for the treatment and prevention of allergies and their preparation and use |
US6045854A (en) | 1997-03-31 | 2000-04-04 | Abbott Laboraties | Nutritional formulations containing oligosaccharides |
WO1999017788A1 (en) * | 1997-10-06 | 1999-04-15 | Abbott Laboratories | Composition of treatment of candidiasis |
US5902743A (en) * | 1998-03-20 | 1999-05-11 | Wisconsin Alumni Research Foundation | Probiotic bifidobacterium strain |
US6841149B1 (en) * | 1998-05-29 | 2005-01-11 | Agri-King, Inc. | Probiotic mixture intended for monogastric animals to control intestinal flora populations |
EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
US7101565B2 (en) * | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
CN1863463B (en) * | 2003-06-23 | 2011-05-04 | 雀巢技术公司 | Nutritional formula for promoting intestine barrier maturation |
US20070207132A1 (en) | 2003-10-24 | 2007-09-06 | N.V. Nutricia | Synbiotic Composition For Infants |
MXPA06006392A (en) | 2003-12-05 | 2007-03-15 | Childrens Hosp Medical Center | Oligosaccharide compositions and use thereof in the treatment of infection. |
US7137361B2 (en) | 2004-06-22 | 2006-11-21 | Federal-Mogul World Wide, Inc. | Cylinder head gasket with one-way coolant flow valve |
EP1714660A1 (en) | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
EP1776877A1 (en) * | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
BRPI0708701A2 (en) | 2006-03-10 | 2011-06-07 | Nutricia Nv | use of a non-digestible water-soluble saccharide |
CN101668437A (en) | 2007-03-13 | 2010-03-10 | N.V.努特里奇亚 | Method of improving skills with a composition comprising non-digestible saccharide |
US8197872B2 (en) * | 2007-05-17 | 2012-06-12 | The Regents Of The University Of California | Human milk oligosaccharides to promote growth of beneficial gut bacteria |
EP2072052A1 (en) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
ES2395838T3 (en) * | 2007-12-21 | 2013-02-15 | Compagnie Gervais Danone | Method to reduce the abdominal contour by administering a bacterium of the Bifidobacterium type |
-
2007
- 2007-12-17 EP EP07123390A patent/EP2072052A1/en not_active Withdrawn
-
2008
- 2008-06-16 PH PH12010501367A patent/PH12010501367B1/en unknown
- 2008-12-05 PT PT88629829T patent/PT2234627T/en unknown
- 2008-12-05 CN CN2008801249067A patent/CN101909644A/en active Pending
- 2008-12-05 MY MYPI2010002780A patent/MY185938A/en unknown
- 2008-12-05 WO PCT/EP2008/066850 patent/WO2009077352A1/en active Application Filing
- 2008-12-05 CA CA2709396A patent/CA2709396A1/en not_active Abandoned
- 2008-12-05 MX MX2010006690A patent/MX2010006690A/en active IP Right Grant
- 2008-12-05 ES ES08862982.9T patent/ES2576642T3/en active Active
- 2008-12-05 RU RU2010129685/15A patent/RU2486910C2/en active
- 2008-12-05 PL PL08862982.9T patent/PL2234627T3/en unknown
- 2008-12-05 EP EP08862982.9A patent/EP2234627B1/en not_active Revoked
- 2008-12-05 SG SG2012092268A patent/SG186657A1/en unknown
- 2008-12-05 BR BRPI0820837-9A patent/BRPI0820837A2/en not_active Application Discontinuation
- 2008-12-05 AU AU2008337646A patent/AU2008337646B2/en active Active
- 2008-12-05 US US12/808,053 patent/US9217133B2/en active Active
- 2008-12-08 UA UAA201008634A patent/UA102830C2/en unknown
-
2010
- 2010-06-16 IN IN4311DEN2010 patent/IN2010DE04311A/en unknown
- 2010-07-16 ZA ZA2010/05088A patent/ZA201005088B/en unknown
-
2012
- 2012-08-17 US US13/588,745 patent/US20120308527A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0768375A1 (en) * | 1992-07-06 | 1997-04-16 | Societe Des Produits Nestle S.A. | Lactic bacteria |
WO1999056754A1 (en) * | 1998-04-30 | 1999-11-11 | Abbott Laboratories | COMPOSITIONS CONTAINING AN α1,2-FUCOSE LINKAGE AND USES THEREOF |
Non-Patent Citations (4)
Title |
---|
LO CASCIO R. G. ET AL.: "Glykoprofiling of Bifidobacterial Consumption of Human Milk Oligosaccharides Demonstrates Strain Specific, Preferential Consumption of Small Chain Glykans Secreted in Early Human Lactation", J. AGRIC. FOOD CHEM., vol. 55, no. 22, 31 October 2007 (2007-10-31), USA, pages 8914 - 8919, XP002471651 * |
MORROW A L ET AL: "Human milk oligosaccharide blood group epitopes and innate immune protectionagainst campylobacter and calicivirus diarrhea in breastfed infants", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 554, 2004, pages 443 - 446, XP009096074, ISSN: 0065-2598 * |
MORROW A. ET AL.: "Human-Milk Glykans That Inhibit Pathogen Binding Protect Breast-feeding Infants against Infectious Diarrhea", THE JOURNAL OF NUTRITION, vol. 135, no. 5, May 2005 (2005-05-01), USA, pages 1304 - 1307, XP002471650 * |
NEWBURG, D. S. ET AL.: "Innate protection conferred by fucosylated oligosaccharides of human milk against diarrhea in breastfed infants", GLYCOBIOLOGY, vol. 14, no. 3, 2004, pages 253 - 263, XP002471649 * |
Cited By (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9132142B2 (en) | 2007-09-07 | 2015-09-15 | The General Hospital Corporation | Use of secretor, Lewis and sialyl antigen levels in clinical samples as predictors of risk for disease |
US9132143B2 (en) | 2007-09-07 | 2015-09-15 | The General Hospital Corporation | Use of secretor, lewis and sialyl antigen levels in clinical samples as predictors of risk for disease |
US11058697B2 (en) | 2009-07-06 | 2021-07-13 | Children's Hospital Medical Center | Inhibiting inflammation with milk oligosaccharides |
US10098903B2 (en) | 2009-07-06 | 2018-10-16 | Children's Hospital Medical Center | Inhibiting inflammation with milk oligosaccharides |
US20120202753A1 (en) * | 2009-07-06 | 2012-08-09 | Children's Hospital Medical Center D/B/A Cincinnati Children's Hospital Medical Center | Inhibiting inflammation with milk oligosaccharides |
US9034847B2 (en) * | 2009-07-06 | 2015-05-19 | Children's Hospital Medical Center | Inhibiting inflammation with milk oligosaccharides |
US11324765B2 (en) | 2009-07-06 | 2022-05-10 | Children's Hospital Medical Center | Inhibiting inflammation with milk oligosaccharides |
US11090321B2 (en) | 2009-07-15 | 2021-08-17 | N.V. Nutricia | Mixture of non-digestible oligosaccharides for stimulating the immune system |
US11135290B2 (en) | 2009-07-15 | 2021-10-05 | N.V. Nutricia | Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit |
RU2773674C2 (en) * | 2009-07-15 | 2022-06-07 | Н.В. Нютрисиа | Mixture of indigestible oligosaccharides to stimulate immune system |
US10588965B2 (en) | 2009-07-15 | 2020-03-17 | N.V. Nutricia | Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit |
US10420784B2 (en) | 2009-07-15 | 2019-09-24 | N.V. Nutricia | Mixture of non-digestible oligosaccharides for stimulating the immune system |
RU2794127C2 (en) * | 2009-07-15 | 2023-04-11 | Н.В. Нютрисиа | Indigestible oligosaccharide mixture for stimulation of immune system |
CN106509916A (en) * | 2010-04-27 | 2017-03-22 | N·V·努特里奇亚 | Use of human milk oligosaccharides in infant nutrition |
CN102946742A (en) * | 2010-04-27 | 2013-02-27 | N·V·努特里奇亚 | Use of human milk oligosaccharides in infant nutrition |
US20130243797A1 (en) * | 2010-11-23 | 2013-09-19 | Norbert Sprenger | Composition comprising hydrolysed proteins and oligisaccharides for treating skin diseases |
US10391141B2 (en) * | 2010-11-23 | 2019-08-27 | Societe Des Produits Nestle S.A. | Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases |
US9763465B2 (en) | 2010-11-23 | 2017-09-19 | Nestec S.A. | Oligosaccharide composition for treating acute respiratory tract infections |
US10813940B2 (en) | 2010-12-31 | 2020-10-27 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
US11524018B2 (en) | 2010-12-31 | 2022-12-13 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US9763970B2 (en) | 2010-12-31 | 2017-09-19 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
US9795623B2 (en) | 2010-12-31 | 2017-10-24 | Abbott Laboratories | Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin C and anti-inflammatory agents |
US9808474B2 (en) | 2010-12-31 | 2017-11-07 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11975014B2 (en) | 2010-12-31 | 2024-05-07 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
EP3335577A1 (en) * | 2010-12-31 | 2018-06-20 | Abbott Laboratories | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota |
EP3335576A1 (en) * | 2010-12-31 | 2018-06-20 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
US11701376B2 (en) | 2010-12-31 | 2023-07-18 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
US11690859B2 (en) | 2010-12-31 | 2023-07-04 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
EP2658546B1 (en) | 2010-12-31 | 2018-12-05 | Abbott Laboratories | Methods of using human milk oligosaccharides for improving airway respiratory health |
US11654156B2 (en) | 2010-12-31 | 2023-05-23 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11633412B2 (en) | 2010-12-31 | 2023-04-25 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US20120171165A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
US10369164B2 (en) | 2010-12-31 | 2019-08-06 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US9539269B2 (en) | 2010-12-31 | 2017-01-10 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
US11464793B2 (en) | 2010-12-31 | 2022-10-11 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US10471081B2 (en) | 2010-12-31 | 2019-11-12 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
EP2658402A1 (en) * | 2010-12-31 | 2013-11-06 | Abbott Laboratories | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota |
US9283240B2 (en) | 2010-12-31 | 2016-03-15 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
US11337990B2 (en) | 2010-12-31 | 2022-05-24 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
EP2658401A2 (en) * | 2010-12-31 | 2013-11-06 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
US11311562B2 (en) | 2010-12-31 | 2022-04-26 | Abbott Laboratories | Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents |
US11207335B2 (en) | 2010-12-31 | 2021-12-28 | Abbott Laboratories | Methods of using human milk oligosaccharides for improving airway respiratory health |
US10709720B2 (en) | 2010-12-31 | 2020-07-14 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
US20120171166A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota |
US11197875B2 (en) | 2010-12-31 | 2021-12-14 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11179406B2 (en) | 2010-12-31 | 2021-11-23 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
US20140249103A1 (en) * | 2010-12-31 | 2014-09-04 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
US10973837B2 (en) | 2010-12-31 | 2021-04-13 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11771102B2 (en) | 2011-06-20 | 2023-10-03 | H.J. Heinz Company Brands Llc | Probiotic compositions and methods |
US11109603B2 (en) | 2011-06-20 | 2021-09-07 | H.J. Heinz Company Brands Llc | Probiotic compositions and methods |
US11446316B2 (en) | 2011-07-22 | 2022-09-20 | Abbott Laboratories | Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
US20230020348A1 (en) * | 2011-07-22 | 2023-01-19 | Abbott Laboratories | Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
US20140294789A1 (en) * | 2011-07-22 | 2014-10-02 | Abbott Laboratories | Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
US10639319B2 (en) | 2011-08-29 | 2020-05-05 | Abbott Laboratories | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
US20140335065A1 (en) * | 2011-08-29 | 2014-11-13 | Abbott Laboratories | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
US10149867B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
US10149870B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
US10626460B2 (en) | 2013-02-21 | 2020-04-21 | Children's Hospital Medical Center | Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease |
US11135232B2 (en) | 2013-11-15 | 2021-10-05 | Societe Des Produits Nestle S.A. | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children |
US10357506B2 (en) | 2013-11-15 | 2019-07-23 | Nestec S.A. | Compositions for use in the prevention or treatment of URT infections in infants or young children at risk |
EP3111942A1 (en) | 2013-11-15 | 2017-01-04 | Nestec S.A. | Compositions for use in the prevention or treatment of urt infections in infants or young children at risk |
US10940158B2 (en) | 2013-11-15 | 2021-03-09 | Societe Des Produits Nestle S.A. | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by C-section |
US11419885B2 (en) | 2013-11-15 | 2022-08-23 | Societe Des Produits Nestle S.A. | Compositions for use in the prevention or treatment of URT infections in infants or young children at risk |
US10842831B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US11931387B2 (en) | 2014-10-31 | 2024-03-19 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US11364270B2 (en) | 2014-10-31 | 2022-06-21 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US11278580B2 (en) | 2014-10-31 | 2022-03-22 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US11213556B2 (en) | 2014-10-31 | 2022-01-04 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US10668116B2 (en) | 2014-10-31 | 2020-06-02 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US10675312B2 (en) | 2014-10-31 | 2020-06-09 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US10842830B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US10835544B2 (en) | 2014-12-08 | 2020-11-17 | Glycom A/S | Synthetic composition for regulating satiety |
US11890293B2 (en) | 2014-12-08 | 2024-02-06 | Glycom A/S | Synthetic composition for treating metabolic disorders |
US10987368B2 (en) | 2014-12-08 | 2021-04-27 | Glycom A/S | Synthetic composition for preventing or treating CVD |
US10881674B2 (en) | 2014-12-08 | 2021-01-05 | Glycom A/S | Synthetic composition for treating metabolic disorders |
WO2016139333A1 (en) | 2015-03-05 | 2016-09-09 | Nestec S.A. | Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children |
EP3265099A4 (en) * | 2015-03-05 | 2018-11-07 | Glycom A/S | Composition and method for treating acute respiratory tract infections |
EP4226927A1 (en) | 2015-03-05 | 2023-08-16 | Société des Produits Nestlé S.A. | Compositions for use in the prevention or treatment of gastrointestinal infections in infants or young children |
WO2016139328A1 (en) | 2015-03-05 | 2016-09-09 | Nestec S.A. | Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children |
US10471084B2 (en) | 2015-03-05 | 2019-11-12 | Glycom A/S | Composition and method for treating acute respiratory tract infections |
US10857167B2 (en) | 2015-04-28 | 2020-12-08 | Children's Hospital Medical Center | Use of oligosaccharide compositions to enhance weight gain |
WO2017215721A1 (en) * | 2016-06-15 | 2017-12-21 | Glycom A/S | Synthetic compositions comprising human milk oligosaccharides for use γν the prevention and treatment of disorders |
US11559539B2 (en) | 2017-08-11 | 2023-01-24 | N.V. Nutricia | Human milk oligosaccharide for improving immune fitness |
US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
EP3981256A4 (en) * | 2019-06-05 | 2023-01-25 | Morinaga Milk Industry Co., Ltd. | Composition |
WO2024013393A1 (en) | 2022-07-15 | 2024-01-18 | Dsm Ip Assets B.V. | Combination of bifidobacterium and fucosylated hmo for use in increasing nmn or nad+ |
WO2024068747A1 (en) * | 2022-09-27 | 2024-04-04 | Société des Produits Nestlé S.A. | Uses of bifidobacterium longum transitional microorganism |
Also Published As
Publication number | Publication date |
---|---|
ZA201005088B (en) | 2017-03-27 |
EP2234627A1 (en) | 2010-10-06 |
PT2234627T (en) | 2016-07-26 |
US9217133B2 (en) | 2015-12-22 |
CA2709396A1 (en) | 2009-06-25 |
EP2072052A1 (en) | 2009-06-24 |
EP2234627B1 (en) | 2016-05-25 |
US20100260720A1 (en) | 2010-10-14 |
UA102830C2 (en) | 2013-08-27 |
AU2008337646B2 (en) | 2014-07-17 |
PH12010501367B1 (en) | 2009-06-25 |
SG186657A1 (en) | 2013-01-30 |
RU2486910C2 (en) | 2013-07-10 |
MY185938A (en) | 2021-06-14 |
MX315565B (en) | 2010-09-10 |
ES2576642T3 (en) | 2016-07-08 |
IN2010DE04311A (en) | 2010-11-12 |
BRPI0820837A2 (en) | 2015-06-16 |
AU2008337646A1 (en) | 2009-06-25 |
MX2010006690A (en) | 2010-09-10 |
US20120308527A1 (en) | 2012-12-06 |
RU2010129685A (en) | 2012-01-27 |
CN101909644A (en) | 2010-12-08 |
PL2234627T3 (en) | 2016-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2234627B1 (en) | Prevention of opportunistic infections in immune-compromised subjects | |
US20220008444A1 (en) | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children | |
US11419885B2 (en) | Compositions for use in the prevention or treatment of URT infections in infants or young children at risk | |
EP3082828B1 (en) | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by c-section | |
EP3071208B1 (en) | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children | |
RU2481844C2 (en) | Prevention and treatment of secondary infections after viral infection | |
US20110064707A1 (en) | Probiotics to improve gut microbiota | |
EP2127661A1 (en) | Probiotics to improve gut microbiotica | |
AU2008324205B2 (en) | Prevention and treatment of secondary infections following viral infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880124906.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08862982 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12808053 Country of ref document: US Ref document number: 2008862982 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2709396 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008337646 Country of ref document: AU Ref document number: 4311/DELNP/2010 Country of ref document: IN Ref document number: 12010501367 Country of ref document: PH Ref document number: MX/A/2010/006690 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008337646 Country of ref document: AU Date of ref document: 20081205 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201008634 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010129685 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PI 2010002780 Country of ref document: MY |
|
ENP | Entry into the national phase |
Ref document number: PI0820837 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100617 |